Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

|Videos|December 13, 2022

Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management

Author(s)Raj Chovatiya, MD, PhD, MSCI, Neal Bhatia, MD

Raj Chovatiya, M.D., Ph.D. and Neal Bhatia, MD comment on the importance of assessing a treatment’s available clinical trial data, ability to control disease severity, and QoL impacts when assessing atopic dermatitis treatment options.

Episodes in this series

EP. 1 Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments

EP. 1 Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments

EP. 2 Atopic Dermatitis Treatment Biological Targets

EP. 2 Atopic Dermatitis Treatment Biological Targets

EP. 3 Use of JAK Inhibitors in Clinical Practice

EP. 3 Use of JAK Inhibitors in Clinical Practice

EP. 4 Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management

EP. 4 Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management

EP. 5 Final Thoughts for Atopic Dermatitis Treatment

EP. 5 Final Thoughts for Atopic Dermatitis Treatment

EP. 6 Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 6 Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 7 Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 7 Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 8 Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 8 Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 9 Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 9 Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 10 Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 10 Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 11 Expert Perspective on the Care of Patients with Atopic Dermatitis

EP. 11 Expert Perspective on the Care of Patients with Atopic Dermatitis

EP. 12 Role of Disease Severity in Topical vs Systemic AD Treatment

EP. 12 Role of Disease Severity in Topical vs Systemic AD Treatment

EP. 13 Efficacy and Safety of JAK inhibitors for AD

EP. 13 Efficacy and Safety of JAK inhibitors for AD

EP. 14 Optimizing Patient Outcomes with JAK Inhibitors

EP. 14 Optimizing Patient Outcomes with JAK Inhibitors

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Phase 2 Data Highlight Roflumilast Cream in Infant AD

ByMaddi Hebebrand, MC, Associate Editor

February 2nd 2026

Kyowa Kirin Takes Full Control of Rocatinlimab Program

ByMaddi Hebebrand, MC, Associate Editor

January 30th 2026

Phase 2 TYK2 Inhibition Shows Promise in AD

ByMaddi Hebebrand, MC, Associate Editor

January 30th 2026

Amlitelimab Demonstrates Efficacy With Every-12-Weeks Dosing in AD Trials

ByMaddi Hebebrand, MC, Associate Editor

January 23rd 2026

Level Up Study Shows Benefits of Switching From Dupilumab to Upadacitinib in AD

ByMaddi Hebebrand, MC, Associate Editor

January 22nd 2026

Latest CME

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Trending on Dermatology Times

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

Introducing Dermatology Times NP/PA Connect

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA